News|Videos|January 17, 2025

Sustainability in Pharmaceutical Manufacturing

Author(s)Susan Haigney

Pharmaceutical Technology® spoke with Charles Ruban, president and CEO, Verdot, about the focus of moving to sustainability practices in pharmaceutical manufacturing.

The pharmaceutical industry has been moving toward more environmentally friendly practices over the past decade. Regulators have also created sustainability requirements, especially in Europe.

“European regulations are particularly stringent on emissions and product lifecycle sustainability, and they have guided a lot of our initiatives such as a co-design, or carbon offset partnerships,” says Charles Ruban, president and CEO, Verdot.

Both small-molecule and large-molecule drug manufacturing have their own challenges, according to Ruban. Biopharmaceutical manufacturing is energy-intensive and creates material waste during production. Ruban says Verdot approaches the challenges of sustainable biopharmaceutical manufacturing by designing energy-efficient equipment that optimizes the use of material.

“We're partnering with suppliers committed to systemic sustainability, so our carbon-neutral initiative reflects the commitment of overcoming those models while enabling appliances to globally reduce their environmental footprint,” says Ruban.

Click the video above to watch the interview.


Related to this article

CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
PharmTech Weekly Roundup—October 2, 2026
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.